Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.45, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | ZBH | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $120.72 | $107.71 |
52-Week Low | $116.16 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid recent dividends, including $0.38 per share in July 2026. News highlights focus on Treasury yield volatility amid inflation data and geopolitical tensions, influencing bond market sentiment.
Outlook is cautious due to bearish technicals and rising yield pressures. Opportunities include government backing and income from dividends, but risks involve Fed rate hike expectations and oil-driven inflation. Investors face volatility from macroeconomic shifts and bond market reactions to policy changes.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
